Rexahn Pharmaceuticals, Inc.  

(Public, NYSEMKT:RNN)   Watch this stock  
Find more results for NYSEAMEX:RNN
-0.016 (-2.03%)
Real-time:   9:46AM EST
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.77 - 0.79
52 week 0.65 - 1.52
Open 0.78
Vol / Avg. 32,680.00/782,256.00
Mkt cap 139.63M
P/E     -
Div/yield     -
EPS -0.11
Shares 178.25M
Beta 0.97
Inst. own 8%
Mar 9, 2015
Rexahn Pharmaceuticals Inc at ROTH Conference - 4:00PM EDT - Add to calendar
Feb 10, 2015
Rexahn Pharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference
Jan 14, 2015
Rexahn Pharmaceuticals Inc at EBD Biotech Showcase
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -20.19% -55.11%
Return on average equity -25.95% -85.74%
Employees 16 -
CDP Score - -


Suite 455, 15245 Shady Grove Road
United States - Map
+1-240-2685300 (Phone)
+1-240-2685310 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Rexahn Pharmaceuticals, Inc. is a development stage biopharmaceutical company dedicated to the discovery, development and commercialization of treatments for cancer and other medical needs. The Company´┐Żs focus is on three clinical stage drug candidates in active development, which are Archexin (Phase IIa completed); RX-3117 (Phase Ib initiated) and Supinoxin (RX-5902, Phase I trial initiated). In addition to these drug candidates, the Company has two clinical stage drug candidates for indications other than cancer: Serdaxin, for major depressive disorder; and Zoraxel, for sexual dysfunction. The Company also has three drug candidates in pre-clinical development: Archexin-Nano,for clinical benefits; RX-0047-Nano, for cancer cell survival, and RX-21101, for treatment of tumors. The Company is also working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems.

Officers and directors

Chang H. Ahn Chairman of the Board, Chief Scientist
Age: 62
Bio & Compensation  - Reuters
Rakesh Soni President, Chief Operating Officer
Age: 58
Bio & Compensation  - Reuters
Peter D. Suzdak Ph.D. Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Tae Heum Jeong Chief Financial Officer, Secretary
Age: 43
Bio & Compensation  - Reuters
Richard J. Rodgers Director
Age: 47
Bio & Compensation  - Reuters
Charles G. Beever Independent Director
Age: 61
Bio & Compensation  - Reuters
Peter C. Brandt Independent Director
Age: 57
Bio & Compensation  - Reuters
Mark P. Carthy Independent Director
Age: 53
Bio & Compensation  - Reuters
Kwang Soo Cheong Independent Director
Age: 53
Bio & Compensation  - Reuters